Pancreatic Cancer Research

ResearcherMayo ClinicActive in the last 2 years

Diego A.S. Toesca

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-3012-7021; OpenAlex author ID A5110578928. Sources: OpenAlex.

Their work

Papers
10 (first author 2, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
29
Papers, trials and grants by year

2017: 2 papers · 2018: 1 paper · 2019: 1 paper · 2020: 2 papers · 2021: 1 paper · 2022: none · 2023: 2 papers · 2024: none · 2025: none · 2026: 1 paper

Papers 10

  1. Radiation Therapy for Pancreatic Cancer: An ASTRO Clinical Practice Guideline. Co-author DOI 10.1016/j.prro.2026.07.002↗
  2. Validation of a Resectability Scoring System for Prediction of Pancreatic Adenocarcinoma Surgical Outcomes. Co-author DOI 10.1245/s10434-023-13120-3↗
  3. ASO Author Reflections: Reducing Subjectivity on Assessment of Pancreatic Cancer Resectability. Co-author DOI 10.1245/s10434-023-13295-9↗
  4. Liver Metastasis-Directed Ablative Radiotherapy in Pancreatic Cancer Offers Prolonged Time Off Systemic Therapy in Selected Patients: Data From a Multi-institu… Co-author DOI 10.1097/mpa.0000000000001822↗
  5. The Utility of Stereotactic Ablative Radiation Therapy for Palliation of Metastatic Pancreatic Adenocarcinoma. First author DOI 10.1016/j.prro.2020.02.010↗
  6. Intensified systemic therapy and stereotactic ablative radiotherapy dose for patients with unresectable pancreatic adenocarcinoma. Co-author DOI 10.1016/j.radonc.2020.07.053↗
  7. Predicting Pancreatic Cancer Resectability and Outcomes Based on an Objective Quantitative Scoring System. Co-author DOI 10.1097/mpa.0000000000001314↗
  8. Management of Borderline Resectable Pancreatic Cancer. Co-author DOI 10.1016/j.ijrobp.2017.12.287↗
  9. Reirradiation with stereotactic body radiation therapy after prior conventional fractionation radiation for locally recurrent pancreatic adenocarcinoma. First author DOI 10.1016/j.adro.2017.01.003↗
  10. Assessing local progression after stereotactic body radiation therapy for unresectable pancreatic adenocarcinoma: CT versus PET. Co-author DOI 10.1016/j.prro.2016.09.002↗

Closest collaborators

The 25 strongest of 29 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Daniel Tandel Chang · 10 shared papers, 2017–2026 · strength 1.47
  2. Albert C. Koong · 6 shared papers, 2017–2023 · strength 0.66
  3. Erqi Liu Pollom · 6 shared papers, 2017–2023 · strength 0.66
  4. Amanda Jeanette Koong · 4 shared papers, 2017–2021 · strength 0.42
  5. George A. Poultsides · 3 shared papers, 2018–2023 · strength 0.34
  6. Brendan Christopher Visser · 3 shared papers, 2018–2023 · strength 0.34
  7. R. Brooke Jeffrey · 2 shared papers, 2019–2023 · strength 0.25
  8. George Albert Fisher · 2 shared papers, 2019–2023 · strength 0.25
  9. Rachna T. Shroff · 1 shared paper, 2026 · strength 0.22
  10. Michael Frederick Bassetti · 1 shared paper, 2026 · strength 0.22
  11. Nina Niu Sanford · 1 shared paper, 2026 · strength 0.22
  12. Michael David Chuong · 1 shared paper, 2026 · strength 0.22
  13. Marsha Reyngold · 1 shared paper, 2026 · strength 0.22
  14. Jessica M. Frakes · 1 shared paper, 2026 · strength 0.22
  15. Karyn A. Goodman · 1 shared paper, 2026 · strength 0.22
  16. Thomas Baptist Brunner · 1 shared paper, 2026 · strength 0.22
  17. Krishan R. Jethwa · 1 shared paper, 2026 · strength 0.22
  18. Ethan Bernard Ludmir · 1 shared paper, 2026 · strength 0.22
  19. Susan Tsai · 1 shared paper, 2026 · strength 0.22
  20. Amol Kumar Narang · 1 shared paper, 2026 · strength 0.22
  21. Dandan Zheng · 1 shared paper, 2026 · strength 0.22
  22. Mary Uan-Sian Feng · 1 shared paper, 2023 · strength 0.16
  23. Theodore Sunki Hong · 1 shared paper, 2021 · strength 0.11
  24. Grace Lee · 1 shared paper, 2021 · strength 0.11
  25. Christopher Leigh Hallemeier · 1 shared paper, 2021 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.